Beta-Nicotinamide Adeninedinucleotide (beta-NAD) Protects and Repairs the Pulmonary Endothelial Cell Barrier in Acute Lung Injury and Acute Respiratory Distress Syndrome and Improves Mortality in Sepsis


Current State of the Art:  

Disruption of the endothelial barrier occurs during inflammatory diseases such as acute lung injury and acute respiratory distress syndrome with an overall mortality rate of 30-40% and results in the movement of fluid and macromolecules into the interstitium and pulmonary air spaces causing pulmonary edema.


Disadvantages of the Current Art: 

In spite of intense research, there is still no successful pharmacologic treatment strategy for lung diseases involving pulmonary endothelial cell barrier breakdown although surfactant, inhaled nitric oxide, corticosteroids, antifungal drugs, and phosphodiesterase inhibitors have been used unsuccessfully.


Advantages of the Invention:  

β-NAD improves the mortality of acute lung injury and acute respiratory distress syndrome by protecting against endothelial cell barrier dysfunction.


Patent Status: PCT Filed


Inventors: Umpathy Siddaramappa, Ph.D; Alexander Verin, Ph.D; Joyce Gonzales, Ph.D


Case Number: GHSU 2010-030

Patent Information:
For Information, Contact:
Augusta University
Umapathy Siddaramappa
Alexander Verin
Joyce Gonzales
Acute Respiratory Distress Syndrome
Lung Injury
© 2021. All Rights Reserved. Powered by Inteum